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Abstract
This study investigated gender differences in cognition in schizophrenia with and without diabetes. Cognition
was assessed in 263 individuals with schizophrenia with age range (40-68): 67 males and 34 females with
schizophrenia with diabetes; and 125 males and 37 females with schizophrenia without diabetes according to
the repeatable battery for the assessment of neuropsychological status (RBANS). Fasting glucose, hemoglobin
A1c (HbA1c) and lipid levels were measured. Results showed that male individuals performed worse on most
cognitive tasks, especially attention, in schizophrenia with than without diabetes. This result was not observed
in female individuals. Also, individuals of both genders showed higher fasting glucose and HbA1c in
schizophrenia with than without diabetes. In schizophrenia with diabetes, males had significantly worse
cognition than females in all cognitive domains. Higher HbA1c, lower high-density lipoprotein, and an earlier
age of onset of schizophrenia were found in males compared with female individuals. HbA1c was negatively
associated with attention and the RBANS total score for males but not for females. In schizophrenia without
diabetes, males showed worse performance in immediate and delayed memory than females. This study
support cognition was worse for males with schizophrenia irrespective of whether they have diabetes or not.
However, diabetes exemplified the gender differences, especially in attention.
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This study investigated gender differences in cognition in schizophrenia with and without 
diabetes. Cognition was assessed in 263 individuals with schizophrenia with age range (40-
68): 67 males and 34 females with schizophrenia with diabetes; and 125 males and 37 
females with schizophrenia without diabetes according to the repeatable battery for the 
assessment of neuropsychological status (RBANS). Fasting glucose, hemoglobin A1c 
(HbA1c) and lipid levels were measured. Results showed that male individuals performed 
worse on most cognitive tasks, especially attention, in schizophrenia with than without 
diabetes. This result was not observed in female individuals. Also, individuals of both 
genders showed higher fasting glucose and HbA1c in schizophrenia with than without 
diabetes. In schizophrenia with diabetes, males had significantly worse cognition than 
females in all cognitive domains. Higher HbA1c, lower high-density lipoprotein, and an 
earlier age of onset of schizophrenia were found in males compared with female individuals. 
HbA1c was negatively associated with attention and the RBANS total score for males but not 
for females. In schizophrenia without diabetes, males showed worse performance in 
immediate and delayed memory than females. This study support cognition was worse for 
males with schizophrenia irrespective of whether they have diabetes or not. However, 
diabetes exemplified the gender differences, especially in attention.    
 

















Schizophrenia is a severe psychiatric disorder characterized by multi-faceted deficits in 
neurocognitive function, including immediate memory, delayed memory, attention, language, 
and visuospatial/constructional domains [1-4]. Cognitive deficits are major impediments to 
social rehabilitation and predict poor clinical outcomes in individuals with schizophrenia [2]. 
Currently, the pathophysiological mechanism of cognitive deficits in schizophrenia is not 
clear.  
Gender differences in cognition in schizophrenia may be due to differences in gender-
related symptomatic expressions of the illness [5]. Therefore, the cognitive deficits 
characteristics of schizophrenia that differ based on gender can indicate areas of altered 
neurobiology and may provide new treatment approaches.  
Gender differences in neuropsychological performance have been found in individuals 
with schizophrenia. Male individuals have an early age of onset, worse negative symptoms, 
and a worse response to antipsychotics than female individuals with schizophrenia [6-9]. A 
recent study found a lower prevalence of diabetes in male than female individuals with 
schizophrenia [10]. Our study and another two studies have indicated that male individuals 
with schizophrenia have more cognitive deficits than females [11-13]. However, other studies 
have reported the opposite or no gender differences in the cognitive deficits of schizophrenia 
[5, 14-16]. These conflicting results support that gender differences in the cognitive deficits 
in individuals with schizophrenia warrant further investigation.  
The prevalence of diabetes has been reported to be two to four times higher in individuals 
with schizophrenia than the general population [17, 18]. Diabetes is also associated with 
cognitive deficits [19, 20]. Studies have found that individuals with schizophrenia with 
















whether diabetes affects the gender differences in the cognitive deficits of individuals with 
schizophrenia has not yet been investigated. 
Several aspects of gender differences in diabetes have been found. Studies have shown 
that female individuals with diabetes have higher insulin levels, higher hemoglobin A1c 
(HbA1c) and poorer glycemic control than males [24]. It is known that insulin resistance, 
hyperglycemia, and lipid metabolic disorders can affect cognitive function [25-28]. Gender 
differences in cognitive deficits in diabetes have also been investigated. Many studies support 
that female individuals with diabetes have more cognitive deficits than males [29-31], 
whereas another study found that male individuals with diabetes had worse cognitive deficits 
than females [32]. Another study has also found no gender differences in the cognitive 
deficits of diabetes [33]. Therefore, whether the gender differences in the cognitive deficits 
are presented in schizophrenia with and without diabetes deserves further investigation. 
The purpose of this study was to determine: (1) whether there are gender differences in the 
cognitive deficits in schizophrenia with and without diabetes; and (2) whether the gender 
differences in cognitive deficits are associated with specific clinical characteristics and 
symptom assessments.  
2. Methods 
2.1. Subjects 
Two hundred and sixty-three individuals with schizophrenia (male/female=192/71) were 
recruited using a cross-sectional naturalistic design at Beijing HuiLongGuan Hospital, a 
Beijing City-owned psychiatric hospital. The data were collected from January 2008 to 
December 2012. The diagnoses for each patient were made by two independent and 
experienced psychiatrists and confirmed by the Structured Clinical Interview for DSM-IV 
















years, and were on stable doses of oral antipsychotic drugs for at least 12 months prior to 
entry into the study. Antipsychotic treatment consisted mainly of monotherapy with atypical 
antipsychotics (n=200), including clozapine (n=116), risperidone (n=66), quetiapine (n=8), 
olanzapine (n=4), aripiprazole (n=6), and typical antipsychotics (n=63), including haloperidol 
(n=16), chlorpromazine (n=13), perphenazine (n=13), sulpiride (n=18), and others (n=3). The 
mean antipsychotic dose (as chlorpromazine equivalents) was 415.3±370.8 mg/day. The 
subjects were all inpatients. They were provided similar living situation and dietary patterns. 
Since admission, all individuals received dietetically balanced hospital meals, which were 
occasionally supplemented by gifts (usually fruit), and individuals had the opportunity of 
about an hour of physical exercise every day.  
All participants underwent fasting blood glucose testing using standard procedures. Blood 
samples are collected in the morning as the same day as the cognitive function assessed. 
Diabetes was diagnosed as persistent fasting hyperglycemia (>126 mg/dL) or plasma glucose 
levels greater than 200 mg/dL at 2 hours after a 75 g oral glucose load. This is consistent with 
the 1999 World Health Organization diagnostic criteria for diabetes mellitus [34]. All of 
individuals with diabetes were receiving conventional medical treatment. The most 
commonly prescribed drugs were oral hypoglycemics such as metformin and repaglinide. 
None of the subjects used insulin.  
Total 358 individuals were screened for the study. 95 individuals were excluded. More 
details, in the schizophrenia with diabetes patients, 26 cases were excluded due to diagnosed 
cerebral vascular disease, coronary heart disease, known neuropsychiatric or central nervous 
system diseases and 37 cases were excluded due to retinopathy, nephropathy, and retinopathy 
accompanied by nephropathy. In the schizophrenia without diabetes, 32 cases were excluded 
due to diagnosed cerebral vascular disease, coronary heart disease, known neuropsychiatric 
















creatinine exceeds the upper limit of normal standard. Since these cardio-cerebrovascular and 
central nervous system diseases are known to be associated with cognitive impairments. Also, 
diabetic retinopathy and nephropathy are strongly linked to impairment in the cognitive 
domains [35, 36]. In addition, none of the individuals showed any audiovisual or motor 
coordination impairments that could affect the cognitive function tests. All participants 
provided signed, informed consent to participate in this study, which was approved by the 
Institutional Review Board of Beijing HuiLongGuan Hospital. 
2.2. Clinical assessment 
Two psychiatrists with more than five years of clinical practical experience, and who were 
blind to the clinical status and treatment conditions, assessed the patient’s psychopathology 
using the positive and negative syndrome scale (PANSS) [37]. To ensure consistent and 
reliable ratings, the two psychiatrists simultaneously attended a training session to 
standardize their use of the PANSS prior to the study. Thereafter, they maintained an intra-
class correlation coefficient of greater than 0.8 on the PANSS at repeated assessments 
throughout the study.  
2.3. Cognitive measures 
The repeatable battery for the assessment of neuropsychological status (RBANS) used to 
measure cognitive function was individually administered by trained investigators and 
supervised by a research psychiatrist [38]. RBANS is composed of 12 subtests used to 
calculate five age-adjusted index scores and a total score [39]. Test indices are: immediate 
memory (composed of list learning and story memory tasks); visuospatial/constructional 
(composed of figure copy and line orientation tasks); language (composed of picture naming 
and semantic fluency tasks); attention (composed of digit span and coding tasks); and delayed 
















group has previously translated RBANS into Chinese and its clinical validity and test-retest 
reliability have already been established among controls and individuals with schizophrenia 
[40]. To ensure consistent and reliable ratings, the two clinical psychiatrists simultaneously 
attended a training session to standardize their use of the RBANS prior to the study. 
Thereafter, they maintained an intra-class correlation coefficient of 0.92 on the RBANS at 
repeated assessments throughout the study. Also, the cognitive raters were blind to 
participants' diabetes status 
2.4. Blood sampling 
Venous blood from a forearm vein was collected from inpatients between 7 and 9 am 
following an overnight fast. All fasting blood glucose, hemoglobin A1c (HbA1c), cholesterol, 
triglyceride, high density lipoprotein, and low density lipoprotein products in the plasma were 
measured by a technician, who was blind to the diagnostic status of the subjects. The identity 
of the subjects was indicated by a code number maintained by the investigator until the 
biochemical analyses were completed. 
2.5. Statistical analysis 
The group comparisons for the demographic and clinical variables used chi-squared or 
fisher exact tests for the categorical variables and student t-tests or analysis of variance 
(ANOVA) for the continuous variables. The RBANS were analysed using a 2 × 2 ANOVA 
representing the between factors of diagnosis (schizophrenia with diabetes vs schizophrenia 
without diabetes) and gender (male vs female). For the RBANS comparisons, age and 
education were also included as covariates in the multivariate analysis of covariance 
(MANCOVA). They were included to examine significant diagnosis differences across 
dependent measures from the RBANS total score and its five cognitive domains. The 
















sizes (<0.1=trivial effect, 0.1–0.3=small effect, 0.3–0.5=medium effect, >0.5=large effect) 
were also calculated for the two-way comparisons and represented the mean difference (in 
standard deviation units) between the groups of interest. In the post hoc comparisons, a 
multiple testing correction was also performed. We assessed relationships between variables 
with Pearson’s product moment correlation coefficients. Multiple regression models were 
used to quantify the amount of variance in cognitive functioning explained by the 
psychopathological variables after controlling for several potential confounders, such as age, 
education, and clinical variables.  
In addition, a mediation analysis was performed to understand the relationship across 
gender, HbA1c and cognitive functions, and to examine whether HbA1c could mediate the 
association between gender and cognitive functions. In the mediation analysis, gender was an 
independent factor, cognitive functions were dependent factors, and HbA1c was the 
moderator, with age and education as the covariates.  
SPSS version 19.0 was used to perform the statistical analysis. Data were presented as 
Mean±SD. All p-values were two-tailed at the significant level of p<0.05. 
3. Results 
3.1. Sample characteristics 
Demographic and clinical characteristics are summarized in Table 1. Overall, there were 
no significant diagnosis differences (schizophrenia with diabetes vs schizophrenia without 
diabetes) in the demographic and clinical characteristics except for higher fasting glucose and 
HbA1c expression (both p<0.001). There were significant gender differences in the age of 
onset, PANSS positive symptoms, PANSS negative symptoms, PANSS general 
psychopathology, HbA1c, and high-density lipoprotein (p<0.01-0.05). However, there were 
















antipsychotic dose (equivalent to chlorpromazine), fasting glucose, cholesterol, triglyceride, 
and low-density lipoprotein between schizophrenia with and without diabetes (all p>0.05). 
There was a significant interaction between diagnosis and gender in HbA1c expression 
(p<0.05).  
Furthermore, data for schizophrenia with and without diabetes were analysed separately to 
assess gender differences in the demographic and clinical characteristics. Male individuals 
showed significantly lower PANSS scores in the general psychopathology subscales, higher 
PANSS scores in the negative symptom subscales, an earlier onset of schizophrenia, and 
lower high-density lipoprotein than females with schizophrenia with diabetes (p<0.01-0.05). 
Male individuals had significantly lower PANSS scores in the positive symptom and general 
psychopathology subscales, and higher PANSS scores in the negative symptom subscales 
than females with schizophrenia without diabetes (p<0.001-0.01). Moreover, both male and 
female individuals had significantly higher fasting glucose and HbA1c expressions in 
schizophrenia with than without diabetes (p<0.001). 
3.2. Gender difference in cognitive performance in schizophrenia with and without diabetes 
Table 2 shows the cognitive test scores for the total RBANS scores and all five indices in 
schizophrenia with and without diabetes. After controlling for age and education, the 
MANCOVA revealed statistically significant differences on the cognitive test scores between 
schizophrenia with and without diabetes (F1,263=5.8, p<0.001). Furthermore, diagnosis 
differences (schizophrenia with diabetes vs schizophrenia without diabetes) were 
significantly for immediate memory, attention, and total RBANS scores (p<0.001-0.05). 
Gender differences were significant for all cognitive test scores (p<0.001-0.05). The 
















In order to decompose the two-way interaction, pair-wise post hoc comparisons showed 
that male individuals had significantly lower levels of RBANS total scores and RBANS 
subscores than females, with effect sizes ranging from 0.53 to 0.82 in schizophrenia with 
diabetes (p<0.01-0.05). Male individuals showed significantly lower levels in immediate 
memory, delayed memory, and total BBANS scores, with effect sizes ranging from 0.40 to 
0.54 in schizophrenia without diabetes (p<0.01-0.05). Male individuals also had significantly 
lower cognitive test scores in almost all cognitive scores except for delayed memory 
(p<0.001-0.05), with effect sizes ranging from 0.35 to 0.83 in schizophrenia with diabetes. 
There were no significant differences in the cognitive index scores in female individuals 
between schizophrenia with and without diabetes.     
3.3. Gender difference in the relationship between cognitive performance and clinical 
variables in schizophrenia with and without diabetes  
Schizophrenia with diabetes: multivariate regression analysis showed that the following 
variables were independently associated with the RBANS total score: HbA1c (beta=-4.665, 
t=-4.948, p<0.001), PANSS negative symptom score (beta=-4.665, t=-4.948, p<0.001, 
p<0.01), PANSS general psychopathology subscale (beta=0.518, t=2.522, p<0.05), and 
gender (beta=5.553, t=2.108, p<0.05). Together, these factors predicted 42% of the variance 
of the total RBANS score. Almost all cognitive indices were negatively correlated with the 
negative PANSS symptom scale in schizophrenia with diabetes except for the 
visuospatial/constructional index. Further analyses were performed separately for the male 
and female individuals with schizophrenia with diabetes to assess gender differences in 
HbA1c associated with cognitive impairment. We hypothesized that the association of 
HbA1c with cognitive function was different in the male and female individuals. Table 3 
shows the correlations between HbA1c and the cognitive performance measures in male and 
















the following parameters: attention (r=−0.31, df=64, p<0.05) and the RBANS total score 
(r=−0.31, df=64, p<0.05). However, no significant association was found between HbA1c 
and the cognitive scores in female individuals. 
Schizophrenia without diabetes: multivariate regression analysis showed that the 
following variables were independently associated with the RBANS total score: education 
(beta=1.526, t=2.362, p<0.05), and PANSS negative symptom score (beta=−0.668, t=−4.450, 
p<0.001). Together, these factors predicted 30% of the variance of the total RBANS score. 
All cognitive indices were negatively correlated with the negative PANSS symptom scale in 
schizophrenia without diabetes. HbA1c was not found to be a contributor to any of the 
RBANS indices or its total score when the males and females were analyzed separately (all 
p>0.05). 
3.4. Mediation analysis for the relationship across gender, HbA1c, and cognitive functions 
As described above, male individuals had significantly lower cognitive function (almost 
all cognitive domains except for delayed memory) and a higher HbA1c concentration than 
female individuals in schizophrenia with diabetes. In the meantime, we found that HbA1c 
was negatively associated with attention for male individuals in schizophrenia with diabetes. 
We thus speculated that the relationship between gender and cognitive function might be 
mediated by HbA1c, and tested this hypothesis by carrying out the mediation analysis as 
below.  
We used gender as an independent factor, attention score as a dependent factor, and 
HbA1c as a moderator, with age and education as the covariates. A statically significant 



















As Fig. 1 illustrates, ‘‘a’’ value, a standardized regression coefficients for the relationship 
between gender and HbA1c was -0.25* (p<0.05), and ‘‘b’’ value, a standardized regression 
coefficients for the relationship between HbA1c and attention, was -0.41*** (p<0.001). Both 
standardized regression coefficients were statistically significant.   
The standardized indirect effect was a * b=0.10. Then we tested the significance of this 
indirect effect using bootstrapping procedures. Unstandardized indirect effects were 
computed for each of the 10,000 bootstrapped samples, and the 95% CI was computed by 
determining the indirect effects at the 2.5th and 97.5th percentiles. The bootstrapped 
unstandardized indirect effect was also 2.48. Most importantly, the 95% CI ranged from 0.74 
to 4.72. Thus, the indirect effect was statistically significant, suggesting that the relationship 
between gender and attention was mediated by HbA1c in schizophrenia with diabetes. 
In addition, we also explored the mediation possibility of HbA1c on the relationship 
between gender and RBANS total score (or other index) in schizophrenia without diabetes. 
However, for all of these analyses, no significant mediation effects were detected. 
4. Discussion 
The main findings of our current study were that: (1) males with schizophrenia had worse 
performance in cognitive function than females irrespective of diabetes, and this was worse in 
schizophrenia with diabetes, especially in attention; (2) HbA1c concentration was 
significantly higher in schizophrenia with than without diabetes in both genders. In addition, 
males had a higher HbA1c than females in schizophrenia with diabetes; and (3) interestingly, 
the significant association between gender and cognition may be mediated by HbA1c in 
schizophrenia with diabetes. 
This study found that diabetes exemplified worse cognition for males than females. To the 
















cognitive deficits than females in all cognitive domains for schizophrenia with diabetes. 
However, gender differences were only indicated in immediate and delayed memory in 
schizophrenia without diabetes. Several studies have indicated that poorer glycemic control 
and higher HbA1c are significantly associated with cognitive deficits [21, 23, 41-45]. Studies 
have also shown that female individuals with diabetes have poorer glycemic control and a 
higher HbA1c concentration than males [24]. Many studies support that female individuals 
have more cognitive impairments than males with diabetes only [29-31]. However, it is 
different for individuals with diabetes only. Our study indicated that male individuals had a 
significantly higher HbA1c concentration than females in schizophrenia with diabetes. The 
HbA1c concentration reflects the mean glucose concentration over a period of 8 to 12 weeks 
from both fasting and postprandial glucose concentrations [45]. In this study, there was no 
significant difference in fasting glucose between males and females in schizophrenia with 
diabetes. However, the fact which male individuals had a higher HbA1c than females may 
reflect chronic long-term poorer glycemic control in males than females in schizophrenia 
with diabetes. Also, we found significant negative correlations for HbA1c with attention and 
the RBANS total score in males with schizophrenia with diabetes, but not for females. 
Moreover, we found that a significant association between gender and cognition was 
mediated by HbA1c in male individuals in schizophrenia with diabetes. Therefore, our results 
support that there is a worse cognitive performance in males than females in schizophrenia 
with diabetes. Furthermore, the males performed cognitive tasks worse in most of the 
cognitive domains, especially in attention in schizophrenia with than without diabetes. Also, 
individuals showed a higher fasting glucose and HbA1c in schizophrenia with than without 
diabetes. All of these results support that cognition is worse in males than females with 
















glycemic control might be the major reason leading to the worsened cognitive performance in 
males with schizophrenia with diabetes.   
Currently, we are not sure exactly why males have a poorer glycemic control than females 
in schizophrenia with diabetes. However, both the current and other previous studies have 
found that males have worse negative symptoms, response to antipsychotics, and cognitive 
deficits than females with schizophrenia [6-9, 11-13]. This may affect more daily life and 
self-medical protection awareness for male individuals and lead to their poorer glycemic 
control. However, the exact mechanisms underlying the male disadvantage in cognitive 
performance and glycemic control in individuals with schizophrenia with diabetes warrants 
further investigation.   
As discussed above, this study prompted a significantly greater gender difference in 
cognitive deficits for schizophrenia with than without diabetes. Previous studies supported 
that the early onset of schizophrenia might predict more serious nervous damage including 
cognitive deficits in individuals with schizophrenia [13, 46]. In the present study, we 
separated the schizophrenia patients into with and without diabetes subgroups. The early 
onset of schizophrenia was present in males rather than females with schizophrenia with 
diabetes, but the gender difference was not present in schizophrenia without diabetes. This 
may be one of the reasons leading to a significantly greater gender difference in cognitive 
deficits in schizophrenia with than without diabetes. Moreover, a previous study showed that 
lower high-density lipoprotein was related to cognitive deficits in individuals with diabetes 
[47]. Compared with females, males showed a significantly low level of high-density 
lipoprotein in schizophrenia with diabetes, but the gender difference was not indicated in 
schizophrenia without diabetes. This may be another reason leading to a significantly greater 
gender difference in cognition in schizophrenia with than without diabetes. In addition, both 
















between the two diseases may be influenced by shared genetic variants that exert pleiotropic 
effects (i.e. the same DNA sequence causes the psychopathology inherent to schizophrenia, 
cognitive deficits, and altered glucose metabolism) [48]. Whether these shared genetic 
variants have higher rates of gender differences in schizophrenia with than without diabetes 
warrants further investigation.   
This study showed that attention was severely affected in male individuals with 
schizophrenia with diabetes. Our study found that male individuals showed a 19.7% decrease 
in attention in schizophrenia with than without diabetes. The poorer glycemic control may be 
one reason for the worsened cognition including attention in male individuals with 
schizophrenia with diabetes. Attention is significantly associated with the function of the 
bilateral prefrontal cortex and superior temporal gyrus brain regions [49]. Thus the 
differences in brain damage in these brain regions such as structure and neurotransmitter 
expression for schizophrenia with and without diabetes also warrants further investigation.     
Males showed worse cognitive deficits than females both in schizophrenia with and 
without diabetes. The results support that the neuronal protective effects of estrogen may also 
play an important role in the female individuals who showed fewer cognitive deficits than 
males. This finding is also supported by a series of other studies [41-43, 50-52]. However, 
some studies have failed to find that estrogen has significant protective effects for cognitive 
function in females rather than males with diabetes only [29, 33]. To confirm whether 
estrogen has neuronal protective effects for females in schizophrenia with and without 
diabetes would require a longitudinal study which cannot be addressed within our current 
cross-sectional design. Moreover, female individuals with schizophrenia showed a greater 
improvement in cognitive deficits with antipsychotic treatment than males [6, 7]. This may be 
another reason why females have better cognitive function than males in schizophrenia with 
















bilateral prefrontal cortex and superior temporal gyrus [49]. Studies have reported that 
individuals with schizophrenia had brain structural abnormalities in the prefrontal, 
hippocampal, and temporal regions [49, 53]. It would be interesting to examine if gender 
differences in cognition in individuals with schizophrenia is related to differences in their 
brain structure. Lastly, post-mortem studies have shown altered abnormal neurotransmitter 
receptor expressions in the prefrontal cortex, temporal lobe, and superior temporal gyrus 
brain regions (such as the muscarinic M1 receptor and gamma-aminobutyric acid (GABA) 
receptor), which may contribute to the pathophysiology of cognitive impairment in 
schizophrenia [54-57]. Therefore, it would be interesting to investigate whether there are 
gender differences among these neurotransmitters in these brain regions in schizophrenia 
with and without diabetes. 
This study also found that cognitive deficits were positively associated with the 
seriousness of negative symptoms both in schizophrenia with and without diabetes. Moreover, 
negative symptoms were worse in males than females in both schizophrenia with and 
schizophrenia without diabetes, which are consistent with our previous and other studies [58-
60]. These results support that gender differences of cognitive deficits are significantly 
associated with severity of negative symptoms in schizophrenia with and without diabetes. It 
needs point out that there were no significant differences of PANSS total and subscores for 
males or female patients in schizophrenia with and without diabetes. Therefore, male patients 
performed worse cognition in schizophrenia with than without diabetes, which support 
gender differences rather than illness severity in the study. In addition, it is also possible that 
the clozapine may affect the results by influencing the diabetes control and complications. 
Our previous study has found that individuals taking clozapine performed worse in 
immediate and delayed memory than those taking typical antipsychotic, but exemplified 
















regression analysis did not find that cognition were associated with the duration of the disease, 
antipsychotic types and body mass index (BMI) in the study. It is worthy of noting that this is 
a cross-sectional design. We could not rule out those potential impacts of severity of 
schizophrenia and antipsychotic drug treatments for this study. Therefore, the currently 
results should be regarded as preliminary results. This limitation should be remedied in the 
future longitudinal study. 
This study found that it is different for individuals with diabetes only, male individuals 
performed a significantly worse cognition than females in schizophrenia with diabetes. We 
also found male individuals had worse cognition than females irrespective of diabetes, but 
this was worse in schizophrenia with diabetes. These results note that health care workers 
need to give more attention to cognitive deficits in male individuals with schizophrenia with 
diabetes, especially in the attention domain. 
There are some limitations in our study. First, although there were no significant 
differences in the gender distribution in schizophrenia with and without diabetes, fewer 
female subjects of chronic individuals were used. This was because female individuals ceased 
their treatment later in the course of the disease, received care via alternate means (family or 
residential facility), or had an improved treatment response and recovery compared to male 
individuals. Second, all of the individuals with schizophrenia in this study were chronic. We 
could not distinguish whether the diabetes in schizophrenia was caused by the antipsychotic 
treatments or whether it existed before the antipsychotic treatments. Third, we did not 
measure postprandial glucose concentration. Therefore, we could not completely confirm that 
male individuals had significantly poorer glycemic control than females even though we have 
found significant higher HbA1c concentration for schizophrenia males compared to females 
in schizophrenia with diabetes. Fourth, diabetes complication and other neurological diseases 
















visual problem which can affect cognitive performance. Patients with severe renal or 
cardiovascular diseases have to be sent to other specialised hospital (difficult to access these 
patients). At this stage, we do not have the data of the duration of diabetes, but we will collect 
these data for future study. Therefore, our results may not represent all schizophrenia with 
diabetes’s situation. Fifth, studies showed that aerobic fitness could improve neurocognition 
in multiple domains in individuals with schizophrenia [62]. In our currently study, although 
individuals with schizophrenia have an opportunity of about physical exercise every day, 
however, we did not record about the details of aerobic exercise for individuals with 
schizophrenia. Therefore, we can not analyse the impact of aerobic exercise in cognitive 
function. This limitation should be remedied in the future investigation. Sixth, although 
individuals with schizophrenia were 40-68 years old, we could not completely exclude the 
potential impact of phase of menstrual on neurocognition and diabetes. 
In conclusion, males with schizophrenia showed worse cognition than females irrespective 
of diabetes, but this was worse in schizophrenia with diabetes. Attention was severely 
affected in males in schizophrenia with diabetes. Poor glycemic control, metabolic 
lipoprotein disorders, and an early age of the onset of schizophrenia might have contributed 
to the worsened cognition for male individuals with schizophrenia with diabetes. It is worth 
noting that health care workers need to give more attention to cognitive deficits in male 
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